## **Solution- and solid-phase synthesis of novel hydantoin and isoxazoline-containing heterocycles**

## **Kyung-Ho Park,***a* **Eric Abbate,***a* **Samir Najdi,***b***† Marilyn M. Olmstead***a* **and Mark J. Kurth\****a***‡**

*a Department of Chemistry, University of California, One Shields Avenue, Davis, CA 95616, USA b Department of Chemistry, Al-Quds University, East Jerusalem, Israel*

## **Exploiting 1,3-dipolar cycloaddition and carbanilide cyclization transformations, novel isoxazolylmethylimidazolidinedione heterocycles have been prepared using both solution- and solid-phase methods.**

The hydantoin moiety has important medicinal<sup>1</sup> as well as agrochemical2,3 activities and a large number of hydantoins have been synthesized for various biological applications.<sup>4</sup> Moreover, the isoxazoline heterocycle has been used extensively to modulate various other biologically active motifs.5 As part of our efforts toward the preparation and biological evaluation of novel hydantoin-containing heterocycles, we disclose here a useful route for the synthesis of isoxazolinecontaining hydantoins<sup>6</sup> as well as present a synthetic strategy applicable to solid-phase combinatorial approaches.



**Scheme 1** *Reagents and conditions*: i, HN=CPh<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temp., ii, allyl bromide, NaH, DMF, room temp.; iii, HCl  $(1 \text{ M})$ ; iv, NaOH  $(1 \text{ M})$ 



**Scheme 2** *Reagents and conditions*: i,  $PhN=C=O$ ,  $CH_2Cl_2$ , room temp.; ii,  $RCH<sub>2</sub>NO<sub>2</sub>$ , PhN=C=O, Et<sub>3</sub>N, THF, 60 °C; iii, NaOEt, EtOH, room temp.

The condensation of glycine ethyl ester HCl salt with benzophenone imine gave benzophenone Schiff base **1**7 (5 mmol scale, 95% yield) which was alkylated with allyl bromide to give protected amino ester **2** (5 mmol scale, 90% yield) (Scheme 1). Hydrolysis of the imine moiety in **2** with aq. HCl and subsequent neutralization of the resulting ammonium salt with aq. NaOH delivered **3** (5 mmol scale, 86%).

The free amine of **3** was reacted with phenyl isocyanate in  $CH<sub>2</sub>Cl<sub>2</sub>$  at ambient temperature for 2 h to give urea  $4$  in 90% yield (5 mmol scale) (Scheme 2). 1,3 Dipolar cycloaddition to the alkene in **4** with a Mukaiyama-generated nitrile oxide8 gave isoxazoline heterocycle  $5^9$  as a C4 $\alpha$  and C4 $\beta$  mixture of



**Fig. 1** Crystallographic projection of 6a  $(R = Ph)$ 



**Scheme 3** Reagents and conditions: i,  $Boc<sub>2</sub>O$ ,  $CH<sub>2</sub>Cl<sub>2</sub>$ , reflux; ii, NaOH (1) M); iii, HCl (1 M); iv, KOH; v, 18-crown-6, Merrifield resin, DMF, 70 °C; vi, TFA, CH<sub>2</sub>Cl<sub>2</sub>; vii, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; viii, RN=C=O, CH<sub>2</sub>Cl<sub>2</sub>, room temp.; ix, R'CH<sub>2</sub>NO<sub>2</sub>, PhN=C=O, Et<sub>3</sub>N, THF, 60 °C; x, Et<sub>3</sub>N, THF, 60 °C

*Chem. Commun***., 1998 1679**

diastereomers (4 mmol scale, **5a** : **5b** : 1 : 1 ratio, yield 60–70%). While separable by flash-column chromatography, each diastereomer of **5** gave the same mixture of two diastereomeric isoxazoloimidazolidinediones **6** upon treatment with NaOEt (1.0 equiv.) in EtOH. Due to this propensity for C2 epimerization during the carbanilide cyclization  $(5a \rightarrow 6a + 6b)$ or  $5b \rightarrow 6a + 6b$ ; 4 mmol scale;  $6a : 6b : 1 : 1$ ; 80% yield), it was in fact most expedient to effect this transformation on the **5a**/**5b** mixture. X-Ray crystallographic analysis§ of  $6a$  ( $R = Ph$ ) (Fig. 1) verified the relative stereochemistries of **5a**/**5b** and **6a**/**6b**.

Our solid-phase approach<sup>10</sup> to isoxazolylmethylimidazolidinedione **6** began with amino ester **3**, which was Boc-protected to give **7** (4 mmol scale, 95% yield) (Scheme 3). Saponification delivered **8** (4 mmol scale, 90% yield) which was coupled with Merrifield resin to give resin **9.**11¶ TFA-mediated removal of the Boc protecting group followed by a resin wash with  $Et_3N-$ CH2Cl2 delivered **10**, the solid-phase analog of **3**. Paralleling the solution results, isocyanate treatment of **10** gave urea **11** and subsequent 1,3-dipolar cycloaddition with a Mukaiyamagenerated nitrile oxide gave **12**. A *ca.* 1 : 1 mixture of isoxazolylmethylimidazolidinedione diastereomers (**6a**/**6b**) was obtained on cyclative release.

We thank the National Science Foundation and Novartis Crop Protection AG for financial support of this research.

## **Notes and References**

† Fulbright Fellow, 1996–1997, University of California, Davis, USA.

‡ E-mail: mjkurth@ucdavis.edu

 $\dot{\S}$  *Crystal data:* for **6a** (R = Ph): C<sub>19</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>, colorless crystals, M = 335.36, orthorhombic, space group *Pbca*, *a* = 9.0062(11), *b* = 11.1037(10),  $c = 32.472(3)$  Å,  $U = 3247.3(6)$  Å<sup>3</sup>,  $Z = 8$ ,  $D_c = 1.372$  Mg  $m^{-3}$ ,  $\mu = 0.776$  mm<sup>-1</sup>,  $R = 0.0392$ ,  $wR = 0.0955$ , GOF = 1.092, T = 130(2) K,  $F(000) = 1408$ , 2189 independent reflections were collected on a Syntex P2<sub>1</sub> diffractometer using graphite-monochromated Cu-K $\alpha$  radiation. CCDC 182/917.

¶ Typical procedure for solid-phase isoxazolylmethylimidazolidinedione synthesis: Boc-protected glycine acid **8** (130 mg, 0.6 mmol) was neutralized (room temp., 1 h) with KOH (1.0 equiv., 0.6 mmol) in EtOH–H<sub>2</sub>O (2:1) and, after removing the solvent and drying *in vacuo*, the potassium salt was dissolved in DMF (20 ml) and reacted with Merrifield resin (300 mg, 0.3 mmol; loading *ca.* 1 mmol Cl  $g^{-1}$ ) and 18-crown-6 (158 mg, 0.6 mmol). The resulting mixture was stirred at 70 °C for 40 h and then washed with DMF (20 ml), THF (20 ml), THF–H<sub>2</sub>O (20 ml $\times$  2), and THF (20 ml). Dried resin 9  $(v_{\text{max}}/cm^{-1}$  1723) was treated with 50% TFA–CH<sub>2</sub>Cl<sub>2</sub> (20 ml) at ambient temperature for 1 h, after which time the resin was washed with  $CH_2Cl_2$  (20 ml), dioxane (20 ml) and  $CH_2Cl_2$  (20 ml $\times$  2). An Et<sub>3</sub>N wash (10% in CH<sub>2</sub>Cl<sub>2</sub>, 20 ml) followed by CH<sub>2</sub>Cl<sub>2</sub> washes (20 ml $\times$  2) gave resin **10** ( $v_{\text{max}}$ /cm<sup>-1</sup> 3383, 1735). Phenyl isocyanate (107 mg, 0.9 mmol) in  $CH<sub>2</sub>Cl<sub>2</sub>$  (20 ml) was added and, after 10 h at ambient temperature, the resin was washed with DMF (20 ml), THF (20 ml) and  $CH<sub>2</sub>Cl<sub>2</sub>$  (20 ml) and dried to give resin 11 (R = Ph;  $v_{\text{max}}/cm^{-1}$  1740, 1700, 1662).  $\alpha$ -Nitrotoluene (123 mg, 0.9 mmol), phenyl isocyanate (214 mg, 1.8 mmol) and  $Et_3N$  (10 ul) were added to this resin in THF (20 ml). After incubating at 60  $^{\circ}$ C for 20 h, washing the resin with DMF (20 ml), THF (20 ml) and  $\rm CH_2Cl_2$  (20 ml) gave resin 12 (R = R' = Ph;  $v_{\text{max}}/cm^{-1}$  1738, 1699) which was finally treated with Et<sub>3</sub>N (1 ml) in THF (20 ml) at 60 °C for 20 h. Resin was removed from the liberated product to give  $6a/6b$  ( $R = R' = Ph$ ) in 35% overall yield from Merrifield resin. These two isomers were easily separated by flash chromatography (EtOAc–hexane 1:2) to give  $6a(R = R' = Ph; 16$ mg, 16% overall yield) and **6b** ( $R = R' = Ph$ ; 19 mg, 19% overall yield). The optimized solid-phase overall yield of  $6a + 6b$  is 35%, which translates to  $ca. 84\%$  yield per step from 8. With catalytic Et<sub>3</sub>N, we saw no evidence for formation of  $\vec{6}$  in  $11 \rightarrow 12$ .

- 1 E. Ware, *Chem. Rev.,* 1950, **46**, 403; A. Spinks and W.S. Waring, *Prog. Med. Chem.*, 1963, **3**, 313; J. Karolakwojciechowska, W. Kwiatkowski and K. Kieckonono, *Pharmazie,* 1995, **50**, 114; W. J. Brouillette, V. P. Jestkov, M. L. Brown and M. S. Akhtar, *J. Med. Chem.,* 1994, **37**, 3289; W. J. Brouillette, G. B. Brown, T. M. Deloreg and G. Liang, *J. Pharm. Sci.,* 1990, **79**, 871.
- 2 C.J. Mappes, E.H. Pommer, C. Rentzea and B. Zeeh, *U.S. Pat.,* 1980, 4,198,423.
- 3 H. Ohta, T. Jikihara, K. Wakabayashi and T. Fujita, *Pestic. Biochem. Physiol.,* 1980, **14**, 153.
- 4 C. Avendano Lopez and G. Gonzalez Trigo, *Adv. Heterocycl. Chem.,* 1985, **38**, 177.
- 5 M. A. Khalil, M. F. Maponya, D.-H. Ko, Z. You, E. T. Oriaku and H. J. Lee, *Med. Chem. Res.,* 1996, **6**, 52; W. C. Groutas, R. Venkataraman, L. S. Chong, J. E. Yooder, J. B. Epp, M. A. Stanga and E.-H. Kim, *Bioorg. Med. Chem.,* 1995, **3**, 125; J. I. Levin, P. S. Chan, J. Coupet, T. K. Bailey, G. Vice, L. Thibault, F. Lai, A. M. Venkatesan and A. Cobuzzi, *Bioorg. Med. Chem. Lett.,* 1994, **4**, 1703.
- 6 K.-H. Park, M. M. Olmstead and M. J. Kurth, *J. Org. Chem*., 1998, **63**, 113; J. Wityak, T. M. Sielecki, D. J. Pinto, G. Emmett, J. Y. Sze, J. Liu, A. E. Tobin, S. Wang, B. Jiang, P. Ma, S. A. Mousa, R. R. Wexler and R. E. Olson, *J. Med. Chem*., 1997, **40**, 50.
- 7 M. J. O'Donnell and R. L. Polt, *J. Org. Chem.*, 1982, 47, 2663.
- 8 T. Mukaiyama and T. Hoshin, *J. Am. Chem. Soc*., 1960, **62**, 5339.
- 9 D. P. Curran, *Adv. Cycloaddition,* 1988, **1**, 129; K. B. G. Torssel, *Nitrile Oxides, Nitrones and Nitronates in Organic Synthesis*, VCH, Weinheim, 1988.
- 10 S. H. DeWitt, J. S. Kiely, C. J. Stankovic, M. C. Schroeder, D. R. Cody and M. R. Pavia, *Proc. Natl. Acad. Sci. U.S.A.,* 1993**, 90***,* 6909; B. A. Dressman, L. A. Spangle and S. W. Kaldor, *Tetrahedron Lett.,* 1996, **37***,* 937.
- 11 R. W. Roeske and P. D. Gesellchen, *Tetrahedron Lett.,* 1976, **38**, 3369.

*Received in Corvallis, OR, USA, 5th May 1998; 8/03400A*